A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes
about
Progressive multifocal leukoencephalopathy: current treatment options and future perspectivesNovel approaches and challenges to treatment of central nervous system viral infectionsNeurological immune reconstitution inflammatory response: riding the tide of immune recoveryProgressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarateProgressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals.Clinical Trials in Neurovirology: Successes, Challenges, and PitfallsImmune reconstitution inflammatory syndrome in a patient with progressive multifocal leukoencephalopathy.Brain Biopsy Is More Reliable than the DNA test for JC Virus in Cerebrospinal Fluid for the Diagnosis of Progressive Multifocal Leukoencephalopathy.Idiosyncratic quinoline central nervous system toxicity: Historical insights into the chronic neurological sequelae of mefloquine.Protective and detrimental roles for regulatory T cells in a viral model for multiple sclerosisUpdate on opportunistic infections in the era of effective antiretroviral therapyInhibition of large T antigen ATPase activity as a potential strategy to develop anti-polyomavirus JC drugsAn animal model for progressive multifocal leukoencephalopathyNeurobehavioral Manifestations of Human Immunodeficiency Virus/AIDS: Diagnosis and TreatmentDeep-Sequence Identification and Role in Virus Replication of a JC Virus Quasispecies in Patients with Progressive Multifocal Leukoencephalopathy.Neuroinfectious diseases: a crisis in neurology and a call for action.Immune surveillance and response to JC virus infection and PML.Progressive multifocal leukoencephalopathy therapyOpportunistic infections and immune reconstitution inflammatory syndrome in HIV-1-infected adults in the combined antiretroviral therapy era: a comprehensive review.Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS).Treatment options for progressive multifocal leukoencephalopathy in HIV-infected persons: current status and future directions.Natalizumab in relapsing-remitting multiple sclerosis.45 years after the discovery of human polyomaviruses BK and JC: Time to speed up the understanding of associated diseases and treatment approaches.Adverse neuropsychiatric effects of antimalarial drugs.Progressive multifocal leukoencephalopathy after liver transplantation can have favorable or unfavorable outcome.Rapid reduction of viruria and stabilization of allograft function by fusidic acid in a renal transplant recipient with JC virus-associated nephropathy.Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis.Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies.Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biologicaProgressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine.Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia.PML therapy: "It's Déjà vu all over again".Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies.Inhibition of Retrograde Transport Limits Polyomavirus Infection In Vivo.Progressive multifocal leukoencephalopathy in the absence of immunosuppression."All the soarings of my mind begin in my blood:" central nervous system complication of Waldenström macroglobulinemia.Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia.Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.A case of developing progressive multifocal leukoencephalopathy while using rituximab and mycophenolate mofetil in refractory systemic lupus erythematosus.
P2860
Q26776236-62C594D2-C1AD-4FF0-AD24-0469789ECD66Q26862449-7765A86B-C24C-4C2B-957A-73EDFDBB3543Q28082309-365D1520-8E6E-4C28-B52E-3856FD1AE0D5Q28083338-92870E04-DABC-4006-A3C1-7689A92AC65DQ30245002-AC21BB19-B8EE-49A6-AB58-3BD1A7AB2072Q30250271-FE5A9DA5-99CB-4283-B429-DD48D5FAD7B4Q30969485-7C5C10BF-D03B-4B01-BECF-DFB17F8B23A5Q32182100-0C37487F-9782-44AF-B554-E3E835470575Q33892018-951D808D-9623-4FC5-A6CD-C410EAC803CFQ33901171-689BB0DF-916F-4140-896F-58787E21A1BCQ34085853-04361D45-B344-4AE6-826B-54CDFA87CC3AQ34647087-0662200E-EE76-41F7-95BA-A4A38D5399FDQ35145409-8AF44AFB-2E3F-4E7D-8E32-C618DE0B3CC2Q36330202-B63F74A1-247A-4C4D-BE46-9CF555831E3EQ37512929-3BF870D9-B7A9-4342-9C07-265008358452Q37608252-12525B4E-0FC0-4988-ABDA-0F658BFD8476Q37678580-5ED73B0B-6765-4FD1-9073-9351F45615EDQ38250227-6A712D81-358C-4EE7-A412-C583B806E478Q38414352-CAAC66E4-1907-427D-8DF1-07F59F3A9DD6Q38577593-5AFF8EE8-22E1-450E-A97C-F5F91E3DE175Q38665891-A40AEE0B-C26A-4F91-AD86-28A0727BAEC3Q38786252-71E2F432-F019-4447-8213-23A52A06035AQ38801394-3C06F410-5C82-4AD4-B61E-285BEB2382A6Q38808162-045C86AD-BFB6-48EA-AA8F-EE063AFCB209Q38844198-A13DEEBA-1CCE-43C8-A371-34E24FCBAC95Q39189713-952FB35B-EEF2-49B7-9015-7D8196F4C302Q39391443-102425C3-4BF8-4440-9055-A45CBB311229Q40039520-B2A120B2-2AF4-4B88-9E45-AA97FB2F785CQ40067748-4491DFCF-2B7F-4E67-BD9F-BA87F150C6CAQ41282310-0D775F6E-76A7-43D2-9A48-B559164735A0Q42155214-3C2664D8-66C5-4F1B-BAD6-FD76D0A1EDBAQ42279234-BF9D66DA-F4FF-45F9-A6C9-752EBF58F4D0Q43280688-FCCDF2D3-6383-4E0A-A390-313C9742915AQ47159198-84472BF0-AA0F-435B-8864-1D26326AF115Q47579884-5A9838EB-73CA-46B2-9BD0-C755EB137682Q48159926-7CA9432D-4D2F-4203-9687-9F568E1C4F32Q50351525-413C5202-A656-432F-8D71-FB1E43073BF7Q52659119-974A5F0E-D5D5-4EEE-994B-22440F13739AQ55429200-A7F74252-37CC-4C02-AF46-B947B5F17491
P2860
A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A study of mefloquine treatmen ...... of predictors of PML outcomes
@en
A study of mefloquine treatmen ...... of predictors of PML outcomes.
@nl
type
label
A study of mefloquine treatmen ...... of predictors of PML outcomes
@en
A study of mefloquine treatmen ...... of predictors of PML outcomes.
@nl
prefLabel
A study of mefloquine treatmen ...... of predictors of PML outcomes
@en
A study of mefloquine treatmen ...... of predictors of PML outcomes.
@nl
P2093
P2860
P1476
A study of mefloquine treatmen ...... of predictors of PML outcomes
@en
P2093
Avindra Nath
Bruce J Brew
David B Clifford
Leonid Gorelik
Paola Cinque
Petra Duda
Zhenming Zhao
P2860
P2888
P304
P356
10.1007/S13365-013-0173-Y
P577
2013-06-04T00:00:00Z